Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice

Anti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for hemophilia A. We investigated the immune response to recombinant human factor VIII Fc (rFVIIIFc) in comparison to BDD-rFVIII and full-length rFVIII (FL-rFVIII) in hemophilia A mice. Repeated administration o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Immunol
Auteurs principaux: Krishnamoorthy, Sriram, Liu, Tongyao, Drager, Douglas, Patarroyo-White, Susannah, Chhabra, Ekta Seth, Peters, Robert, Josephson, Neil, Lillicrap, David, Blumberg, Richard S., Pierce, Glenn F., Jiang, Haiyan
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4936482/
https://ncbi.nlm.nih.gov/pubmed/26775174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellimm.2015.12.008
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires